Wells Fargo & Company Enlivex Therapeutics Ltd. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 9,184 shares of ENLV stock, worth $9,643. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,184
Previous 9,184
-0.0%
Holding current value
$9,643
Previous $15,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ENLV
# of Institutions
27Shares Held
2.75MCall Options Held
20.8KPut Options Held
3K-
Armistice Capital, LLC New York, NY2.21MShares$2.32 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny634KShares$665,5390.0% of portfolio
-
Morgan Stanley New York, NY270KShares$283,1370.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny159KShares$166,9410.0% of portfolio
-
Sigma Investment Counselors Inc28KShares$29,4000.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $19.3M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...